or Try an Advanced Search...

    Technical Analysis for BCEL - Atreca, Inc.

    Grade Last Price % Change Price Change
    F 0.09 -3.84% 0.00
    BCEL closed up 1.08 percent on Wednesday, May 8, 2024, on 18 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical BCEL trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction -3.84%
    NR7-2 Range Contraction -3.84%
    Narrow Range Bar Range Contraction -3.84%
    Earnings Movers Other -3.84%
    NR7 Range Contraction -2.80%
    Narrow Range Bar Range Contraction -2.80%
    Upper Bollinger Band Walk Strength -2.80%
    Upper Bollinger Band Walk Strength 0.11%
    Upper Bollinger Band Touch Strength 0.11%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    Older End-of-Day Signals for BCEL ...

       Recent Intraday Alerts

    Alert Time
    20 DMA Support about 3 hours ago
    10 DMA Support about 3 hours ago
    Down 5% about 3 hours ago
    Fell Below Previous Day's Low about 3 hours ago
    Down 3% about 3 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    BCEL Chart by TradingView
    Basic chart:

    Profile

    Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. While more traditional oncology drug discovery approaches attempt to generate antibodies against known targets, Atreca’s approach relies on the human immune system to direct it to unique antibody-target pairs from patients experiencing a clinically meaningful, active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Biopharmaceutical Life Sciences Immunology Solid Tumors Immune System Antibodies Tumor Cancer Immunotherapy Monoclonal Antibody Drug Discovery Antibody Glycoproteins Immune Response Immunotherapeutics Agenus

    Is BCEL a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jan 11 Sera Prognostics, Atreca spike after Baker Bros investments
    Jan 11 Why Richardson Electronics Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket
    Dec 26 Atreca to sell antibody-related assets and materials to Immunome for $12.5M
    Dec 26 Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
    Nov 14 Atreca GAAP EPS of -$0.92
    Nov 14 Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives
    See more BCEL news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.2642
    52 Week Low 0.052
    Average Volume 426,200
    200-Day Moving Average 0.28
    50-Day Moving Average 0.12
    20-Day Moving Average 0.08
    10-Day Moving Average 0.09
    Average True Range 0.01
    RSI (14) 49.75
    ADX 20.27
    +DI 16.35
    -DI 13.04
    Chandelier Exit (Long, 3 ATRs) 0.07
    Chandelier Exit (Short, 3 ATRs) 0.10
    Upper Bollinger Bands 0.10
    Lower Bollinger Band 0.07
    Percent B (%b) 0.87
    BandWidth 28.50
    MACD Line -0.01
    MACD Signal Line -0.01
    MACD Histogram 0.0047
    Fundamentals Value
    Market Cap 3.09 Million
    Num Shares 32.9 Million
    EPS -2.50
    Price-to-Earnings (P/E) Ratio -0.04
    Price-to-Sales 0.00
    Price-to-Book 0.91
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.10
    Resistance 3 (R3) 0.10 0.10 0.10
    Resistance 2 (R2) 0.10 0.09 0.10 0.10
    Resistance 1 (R1) 0.10 0.09 0.10 0.10 0.10
    Pivot Point 0.09 0.09 0.09 0.09 0.09
    Support 1 (S1) 0.09 0.09 0.09 0.09 0.09
    Support 2 (S2) 0.09 0.09 0.09 0.09
    Support 3 (S3) 0.09 0.09 0.09
    Support 4 (S4) 0.09